Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans (Q57825111)

6

0 references

author name string

E K Tarkiainen

1

0 references

J T Backman

2

0 references

P J Neuvonen

4

0 references

M Schwab

Clinical Pharmacology & Therapeutics

5

0 references

language of work or name

English

0 references

publication date

16 May 2012

0 references

language of work

0 references

volume

92

0 references

issue

1

0 references

page(s)

68-71

0 references

cites work

Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Structure, function and regulation of carboxylesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

The mammalian carboxylesterases: from molecules to functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Carboxylesterase 1 (Ces1): from monocyte marker to major player

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Neuroexcitatory actions of Tamiflu and its carboxylate metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Frequencies of Single-Nucleotide Polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 Genes in a Finnish Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13

Global patterns of genetic diversity and signals of natural selection for human ADME genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.13